THE OBSERVATORY :: NEWS TRENDS ANALYSIS


Scientists discover new patho- genic mechanism in hematologi- cal malignancies


photo credit Image by Claire51700 from Pixabay Fast Facts


In a study of children born after a pregnancy of less than 24 weeks, nearly all (96 percent) had some degree of development disorder. According to the study, from the


University of Gothenburg, neuropsy- chiatric and somatic diagnoses are


prevalent as these extremely preterm infants grow into adulthood.


Among these children born before 24 weeks of pregnancy:


XXX Text here


Source: xxx One-year survival rates for infants born alive


2014–2016 with gestational age 22 and 23 weeks were 30% and 61%


75 %


Of the premature babies had neuro- psychiatric impairments,


30 %


Of the premature infants had Attention- Deficit/Hyperactivity Disorder, ADHD.


20 years


the survival rate among extremely premature babies has risen sharply, especially in those born in gestational weeks 22 and 23


88 %


Of the premature infants had other medical diagnoses, such as Asthma (63 percent) or postnatal growth restriction (39 percent).


55 %


Of the premature infants required habilitation support.


Source: University of Gothenburg, Neuro- developmental disorders and somatic diag- noses in a national cohort of children born before 24 weeks of gestation; https://www. gu.se/en/news/wide-ranging-diagnoses-in- children-born-before-24-weeks-gestation


6 MAY 2022 MLO-ONLINE.COM


Scientists at Yale Cancer Center have discovered new consequences of spe- cific gene mutations that play a role in the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), according to a news release. Approximately half the patients di-


agnosed with MDS and 10% of patients with AML are found to have splicing factor mutations leading to ineffective blood cell production and malignancy. The new research revealed that mu- tations in the splicing factor U2AF1 improve the ability of the cancer cells to respond to and survive stress. The findings were published in Molecular Cell.


Splicing factor mutations are particu-


larly common in MDS and leukemia but also occur in other cancers. RNA splicing is a fundamental process ac- counting for cell diversity. The genetic code is transcribed from DNA to RNA molecules, which have to be processed to function properly. During splicing, RNA molecules are cut and select pieces are reconnected by splicing factors, including U2AF1. Mutations in splicing factors result in mistakes in this process.


In the new study, the research team demonstrated that mutations in U2AF1 alter RNA binding, splicing, and turnover of numerous RNAs, and en- hance the formation of so-called stress granules, biomolecular condensates of RNAs and proteins, that mediate cellu- lar adaptation to stress. This improved stress response may explain the clonal advantage of mutant cells and the de- velopment of MDS or AML. “The discovery that U2AF1 muta- tions enhance stress granule formation may open novel avenues to prevent or treat myelodysplastic syndromes and acute myeloid leukemia,” said Giulia Biancon, PhD, Postdoctoral Associate in the Halene Laboratory at Yale Cancer Center and lead author on the paper. “This discovery was possible by de-


veloping new experimental and ana- lytic methods integrating big data. The mechanism of enhanced stress granule formation was not easy to detect be- cause it’s not caused by a single large change to one RNA molecule, but by the sum of many small changes to hun- dreds of RNA molecules,” said Toma Tebaldi, PhD, Assistant Professor at the University of Trento, Adjunct Assistant Professor at Yale School of Medicine, and co-senior author on the paper.


MDS are most common in patients


over 70 years old and are conditions that can occur when the blood- forming cells in the bone marrow become abnormal. AML also starts in the bone marrow and is most com- monly diagnosed in older patients, but most often it quickly moves into the blood, as well.


CDC reveals effect of COVID-19 on tuberculosis


New data suggests that the pandemic has had a substantial effect on TB trends in the United States, according to the Centers for Disease Control (CDC). Before COVID-19, TB disease diag- noses typically declined between 1% and 2% each year. The 2020 and 2021 declines may be related to factors as- sociated with the COVID-19 pandemic, including a true reduction in incidence as well as delayed or missed TB diag- noses.


Efforts to prevent COVID-19, such


as wearing masks and distiancing, may also reduce the spread of TB. Widespread disruptions to health- care during the COVID-19 pandemic may have delayed TB diagnoses. The COVID-19 pandemic has strained public health services, including TB prevention and control services. Similarities in symptoms between


COVID-19 and TB disease may have led to missed TB diagnoses. Case reports have revealed some people with TB disease were evaluated for COVID-19 — but not tested for TB — during multiple encounters with healthcare systems. Initial misassumptions might have contributed to missed diagnoses, or delayed diagnoses until more ad- vanced stages of disease. TB prevention and control activities are essential public health functions for communities throughout the United States. To assist in these efforts, CDC launched the Think. Test. Treat TB campaign to help raise awareness of TB and recognize the importance of TB prevention. Philip LoBue, MD, FACP, FCCP, Director of CDC’s Division of Tuber- culosis Elimination, said, “Delayed or missed tuberculosis disease diagnoses are threatening the health of people with TB disease and the communities where they live. A delayed or missed TB diagnosis leads to TB disease progres- sion and can result in hospitalization or death – and the risk of transmitting TB to others. The nation must ensure that healthcare providers understand how to diagnose and distinguish TB disease from potential cases of COVID-19.”


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52